The abstract reports selective toxicity of AMSA-2 and MPB-7 in UHRF1-high cancer lines versus normal cells but doesn't explain the underlying mechanism. This selectivity principle could inform therapeutic strategies for neurodegenerative diseases involving aberrant DNA methylation. Gap type: unexplained_observation Source paper: Disrupting the epigenetic alliance: structural insights and therapeutic strategies targeting DNMT1-UHRF1. (2025, Functional & integrative genomics, PMID:40960568)
Landscape Summary: Why do DNMT1-UHRF1 inhibitors show preferential cytotoxicity in cancer vs non-transformed cells? is a 0.69 priority gap in epigenetic therapeutics. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
Why do DNMT1-UHRF1 inhibitors show preferential cytotoxicity in cancer vs non-transformed cells? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: